CN103501774A - 含有他喷他多的半固体含水药用组合物 - Google Patents

含有他喷他多的半固体含水药用组合物 Download PDF

Info

Publication number
CN103501774A
CN103501774A CN201280011678.9A CN201280011678A CN103501774A CN 103501774 A CN103501774 A CN 103501774A CN 201280011678 A CN201280011678 A CN 201280011678A CN 103501774 A CN103501774 A CN 103501774A
Authority
CN
China
Prior art keywords
weight
pharmaceutical composition
still
tapentadol
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280011678.9A
Other languages
English (en)
Chinese (zh)
Inventor
U.莱茵霍尔德
M.席勒
E.武尔斯滕
S.K.K.英赫尔布雷希特
R.C.A.恩布雷希茨
U.法伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of CN103501774A publication Critical patent/CN103501774A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201280011678.9A 2011-03-04 2012-03-02 含有他喷他多的半固体含水药用组合物 Pending CN103501774A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
US61/449329 2011-03-04
EP11003603 2011-05-03
EP11003603.5 2011-05-03
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Publications (1)

Publication Number Publication Date
CN103501774A true CN103501774A (zh) 2014-01-08

Family

ID=44652117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280011678.9A Pending CN103501774A (zh) 2011-03-04 2012-03-02 含有他喷他多的半固体含水药用组合物

Country Status (24)

Country Link
US (3) US9446008B2 (OSRAM)
EP (3) EP3766489B1 (OSRAM)
JP (3) JP6027549B2 (OSRAM)
KR (2) KR102039320B1 (OSRAM)
CN (1) CN103501774A (OSRAM)
AU (2) AU2012224954C1 (OSRAM)
BR (1) BR112013022556A8 (OSRAM)
CA (1) CA2828637C (OSRAM)
CY (1) CY1119725T1 (OSRAM)
DK (1) DK2680834T3 (OSRAM)
EA (2) EA025194B1 (OSRAM)
ES (2) ES2654407T3 (OSRAM)
HR (1) HRP20171836T1 (OSRAM)
HU (1) HUE037491T2 (OSRAM)
IL (2) IL227826B (OSRAM)
LT (1) LT2680834T (OSRAM)
MX (2) MX374468B (OSRAM)
NO (1) NO2680834T3 (OSRAM)
PL (1) PL2680834T3 (OSRAM)
PT (2) PT3766489T (OSRAM)
RS (1) RS56692B1 (OSRAM)
SI (1) SI2680834T1 (OSRAM)
WO (1) WO2012119729A1 (OSRAM)
ZA (1) ZA201306480B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996533A (zh) * 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102051800B1 (ko) 2011-03-04 2019-12-04 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
CA2828637C (en) * 2011-03-04 2019-06-11 Grunenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
WO2015014980A1 (en) * 2013-08-02 2015-02-05 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
PT3273953T (pt) * 2015-03-27 2019-04-01 Gruenenthal Gmbh Formulação estável para administração parentérica de tapentadol
WO2020020879A1 (en) * 2018-07-24 2020-01-30 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Topical emulsion of an anticholinergic compound
WO2020190872A1 (en) 2019-03-18 2020-09-24 Sunstar Americas, Inc. Oral care composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067651A2 (de) * 2001-02-28 2002-09-06 Grünenthal GmbH Pharmazeutisch salze
WO2008110323A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-phenyl-3-dimethylamino-propanverbindungen zur therapie des neuropathieschmerzes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
ES2399880T3 (es) 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
CA2498410A1 (en) 2002-09-13 2004-03-25 Cydex, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
JP2007538091A (ja) 2004-05-17 2007-12-27 ファーマコフォア・インコーポレイテッド 痛みを処置または予防するための組成物および方法
SI1612203T1 (sl) 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
EP1786403B1 (de) 2004-07-01 2013-07-24 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
AU2006239313A1 (en) 2005-04-28 2006-11-02 Najib Babul Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
CN102671195B (zh) 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
NZ571442A (en) 2006-04-28 2011-09-30 Gruenenthal Chemie Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol for treating pain
PL2046726T3 (pl) 2006-07-24 2010-06-30 Janssen Pharmaceutica Nv Wytwarzanie (2R,3R)-3-metoksyfenylo)-N,N,2-trimetylopentanoaminy
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
PL2596784T3 (pl) 2007-11-23 2017-06-30 Grünenthal GmbH Kompozycje tapentadolu
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
JP6216489B2 (ja) 2008-10-30 2017-10-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規の、効力のあるタペンタドール剤形
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
WO2011083304A1 (en) * 2010-01-05 2011-07-14 Shire Llc Prodrugs of opioids and uses thereof
RU2553350C2 (ru) * 2010-03-30 2015-06-10 Фосфейдженикс Лимитед Трансдермальные пластыри
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
CA2828637C (en) 2011-03-04 2019-06-11 Grunenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067651A2 (de) * 2001-02-28 2002-09-06 Grünenthal GmbH Pharmazeutisch salze
WO2008110323A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-phenyl-3-dimethylamino-propanverbindungen zur therapie des neuropathieschmerzes
EP2117525A1 (de) * 2007-03-12 2009-11-18 Grünenthal GmbH Verwendung von 1-phenyl-3-dimethylamino-propanverbindungen zur therapie des neuropathieschmerzes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996533A (zh) * 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂

Also Published As

Publication number Publication date
EP3766489B1 (en) 2022-03-16
CA2828637C (en) 2019-06-11
ES2910085T3 (es) 2022-05-11
AU2012224954A1 (en) 2013-09-19
EP3290029B1 (en) 2020-09-02
HRP20171836T1 (hr) 2017-12-29
IL227826A0 (en) 2013-09-30
KR102039320B1 (ko) 2019-11-01
JP2014506900A (ja) 2014-03-20
WO2012119729A1 (en) 2012-09-13
DK2680834T3 (en) 2017-12-04
PT3766489T (pt) 2022-04-07
SI2680834T1 (en) 2018-01-31
US20120225950A1 (en) 2012-09-06
EP2680834A1 (en) 2014-01-08
AU2012224954B2 (en) 2016-10-20
AU2012224954C1 (en) 2017-04-06
EA033171B1 (ru) 2019-09-30
IL227826B (en) 2018-04-30
MX344473B (es) 2016-12-16
JP6027549B2 (ja) 2016-11-16
BR112013022556A2 (pt) 2016-12-06
BR112013022556A8 (pt) 2018-01-16
EP3290029A1 (en) 2018-03-07
HUE037491T2 (hu) 2018-09-28
US20180133174A1 (en) 2018-05-17
KR20180116463A (ko) 2018-10-24
JP6670283B2 (ja) 2020-03-18
JP6259042B2 (ja) 2018-01-10
IL258357A (en) 2018-05-31
MX374468B (es) 2025-03-06
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
ZA201306480B (en) 2014-05-28
CA2828637A1 (en) 2012-09-13
EA025194B1 (ru) 2016-11-30
ES2654407T3 (es) 2018-02-13
CY1119725T1 (el) 2018-06-27
AU2017200040B2 (en) 2018-09-06
NO2680834T3 (OSRAM) 2018-03-17
AU2017200040A1 (en) 2017-02-02
KR20140013020A (ko) 2014-02-04
KR101911362B1 (ko) 2018-10-25
EP3766489A1 (en) 2021-01-20
EA201600442A1 (ru) 2017-02-28
RS56692B1 (sr) 2018-03-30
JP2017039756A (ja) 2017-02-23
LT2680834T (lt) 2018-01-10
PL2680834T3 (pl) 2018-03-30
EA201300988A1 (ru) 2014-06-30
US9446008B2 (en) 2016-09-20
JP2018065839A (ja) 2018-04-26
PT2680834T (pt) 2018-01-25
EP2680834B1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
JP6259042B2 (ja) タペンタドールを含む半固形の水性医薬組成物
CN1152689C (zh) 活性维生素d3乳状液类型的洗剂
JP4828563B2 (ja) 水虫治療用外用剤
JP2017081901A (ja) 水中油型乳化組成物
JP6503627B2 (ja) 医薬液体組成物
ES2822023T3 (es) Composición farmacéutica acuosa semisólida que contiene tapentadol
WO2007086582A1 (ja) ２２－オキサ－１α,２５－ジヒドロキシビタミンＤ3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
KR20230124624A (ko) 에피나스틴 또는 그의 염을 함유하는 도포 투여용 의약조성물
HK1194966A (en) Semisolid aqueous pharmaceutical composition containing tapentadol
HK1194966B (en) Semisolid aqueous pharmaceutical composition containing tapentadol
WO2025222268A1 (en) Topical compositions and methods for treating atrophic vaginitis
JP2025036319A (ja) クロルフェニラミンマレイン酸塩を含有する医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140108

RJ01 Rejection of invention patent application after publication